{"disease":{"id":"central-retinal-vein-occlusion","name":"central retinal vein occlusion"},"drugs":{"marketed":[{"drug_id":"aflibercept","indication_name":"Central retinal vein occlusion with macular edema","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vegf Trap","generic_name":"AFLIBERCEPT","company_name":"Regeneron","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor A","drug_class":"Vascular Endothelial Growth Factor Inhibitor","quality_score":55,"revenue":"9800","mechanism":""},{"drug_id":"dexamethasone","indication_name":"Central retinal vein occlusion with macular edema","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Decadron","generic_name":"dexamethasone","company_name":"Generic (originally Merck)","drug_phase":"marketed","molecular_target":"Annexin A1, Interleukin-4, Androgen receptor","drug_class":"Corticosteroid [EPC]","quality_score":44,"revenue":null,"mechanism":""},{"drug_id":"eylea","indication_name":"Central retinal vein occlusion with macular edema","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Eylea","company_name":"Texas Retina Associates","drug_phase":"marketed","molecular_target":"Placenta growth factor, Vascular endothelial growth factor A, Vascular endothelial growth factor B","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"lucentis","indication_name":"Central retinal vein occlusion with macular edema","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Lucentis","company_name":"Santen Inc.","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor A","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"ranibizumab-nuna","indication_name":"Central retinal vein occlusion with macular edema","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BYOOVIZ","generic_name":"RANIBIZUMAB-NUNA","company_name":"SAMSUNG BIOEPIS CO LTD","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor A","drug_class":"","quality_score":null,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":5,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05476926","title":"A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":6000,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT04740931","title":"A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Central Retinal or Hemiretinal Vein Occlusion","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":729,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true},{"nct_id":"NCT03810313","title":"Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":493,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT01976312","title":"Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Central Retinal Vein Occlusion (CRVO)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":252,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT03223714","title":"Conbercept Ophthalmic Injection for Patients of Central Retinal Vein Occlusion","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":242,"lead_sponsor_name":"Chengdu Kanghong Biotech Co., Ltd.","has_results":false},{"nct_id":"NCT02800642","title":"Evaluation of a Treat and Extend Regimen of Intravitreal Aflibercept for Macular Edema Secondary to CRVO","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":162,"lead_sponsor_name":"Bayer","has_results":true},{"nct_id":"NCT05832996","title":"Cool vs Room-temperature Artificial Tears","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":124,"lead_sponsor_name":"University of Iowa","has_results":true},{"nct_id":"NCT04444492","title":"Combination of Ranibizumab and Targeted Laser Photocoagulation","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":110,"lead_sponsor_name":"University of Giessen","has_results":false},{"nct_id":"NCT04601701","title":"Central Retinal Vein Occlusion (CRVO) Treatment With Bevacizumab and Dexamethasone or Bevacizumab Only.","phase":"NA","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"He Eye Hospital","has_results":false},{"nct_id":"NCT02585401","title":"Evaluation of Physician Knowledge of Safety and Safe Use Information for Aflibercept in Canada","phase":"","overall_status":"COMPLETED","enrollment_count":99,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT04667910","title":"601 Versus Ranibizumab in Patients With Central Retinal Vein Occlusion (CRVO)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":60,"lead_sponsor_name":"Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.","has_results":false},{"nct_id":"NCT04793100","title":"Spontaneous Retinal Artery Pulses (SPARs) as a Prognostic Determinant of Central Retinal Vein Occlusions (CRVO) in Patients With or Without Intravitreal Aflibercept Injections","phase":"NA","overall_status":"COMPLETED","enrollment_count":60,"lead_sponsor_name":"Fondation Ophtalmologique Adolphe de Rothschild","has_results":false},{"nct_id":"NCT04290195","title":"Use of Ziv Aflibercept in Different Retinal Diseases","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":55,"lead_sponsor_name":"Amin El Sayed Nawar","has_results":false},{"nct_id":"NCT05282420","title":"Ranibizumab Versus Aflibercept for CRVO in Young Patients.","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":40,"lead_sponsor_name":"South Valley University","has_results":false},{"nct_id":"NCT06708624","title":"Ocular Safety and Usability Study for FYB201 PFS","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":31,"lead_sponsor_name":"Formycon AG","has_results":false},{"nct_id":"NCT02503540","title":"Peripheral and Macular Retinal Vascular Perfusion and Leakage in DME and RVO","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":31,"lead_sponsor_name":"Justis Ehlers","has_results":true},{"nct_id":"NCT04812977","title":"Comparison of Intravitreal Anti-VEGF Versus Combination Therapy in Central Retinal Vein Occlusion","phase":"NA","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"Hayatabad Medical Complex","has_results":true},{"nct_id":"NCT06708637","title":"Ocular Safety and Usability Study for FYB203 PFS","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"Formycon AG","has_results":false},{"nct_id":"NCT03981549","title":"Treatment of Central Retinal Vein Occlusion Using Stem Cells Study","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":16,"lead_sponsor_name":"The Emmes Company, LLC","has_results":true},{"nct_id":"NCT03417401","title":"Surgical Stabilizer Assisted RVC With rtPA for CRVO","phase":"PHASE1","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Universitaire Ziekenhuizen KU Leuven","has_results":false}],"total":20},"guidelines":[],"source":"Drug Landscape verified database"}